Pharmed Pharmaceuticals Pty Ltd has acquired Amalgamated Pharmaceuticals Ltd
Pharmed Pharmaceuticals (Pty) Ltd (Pharmed) has acquired the business assets (excluding debtors and liabilities) of Amalgamated Pharmaceuticals Ltd (Amalgamated), a pharmaceutical wholesale and distribution company, for an undisclosed consideration.
Pharmed is a supplier and distributor of healthcare related products, including ethical, generic, patent, homeopathic, surgical, dental and veterinary products and medical equipment, reagents and supplies to dispensing doctors, retail pharmacies, private hospitals and other allied healthcare professionals. The acquisition of the Amalgamated business meets Pharmed’s strategic growth objective.
Amalgamated was formed in 1997 by the merger of five major pharmaceutical distribution companies, which boasted a track record of more than 60 years’ service. Amalgamated is a full-line, nation-wide wholesaler that is focused exclusively on the pharmaceutical market with its head office in Johannesburg and a satellite office in Durban.
Oaklins' team in South Africa acted as financial advisor to Pharmed in this transaction.
Talk to the deal team
Related deals
Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Learn moreRare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn more